Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.

Molecular cancer therapeutics - 1 Nov 2015

Le Gall Marianne, Crépin Ronan, Neiveyans Madeline, Auclair Christian, Fan Yongfeng, Zhou Yu, Marks James D, Pèlegrin André, Poul Marie-Alix

Abstract excerpt

KIT is a cell surface tyrosine kinase receptor whose ligand stem cell factor (SCF) triggers homodimerization and activation of downstream effector pathways involved in cell survival, proliferation, homing, or differentiation. KIT-activating mutations are major oncogenic drivers in subsets of acute myeloid leukemia (AML), in mast cell leukemia, and in gastrointestinal stromal tumors (GIST). The overexpression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to CHO Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cricetulus

Share to Leukemia

Share to Proto-Oncogene Proteins c-kit

Share to Sf9 Cells

Share to Single-Chain Antibodies

Share to Spodoptera

Source

Open in PubMed Open full text

Identifiers

PMID: 26358753
DOI: 10.1158/1535-7163.MCT-15-0321
PMCID: PMC6013065

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.PMID 26358753Read ↗

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.Semantic proximity Read ↗

C-KIT signaling in cancer treatment.Semantic proximity Read ↗

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.Semantic proximity Read ↗

KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.Semantic proximity Read ↗

The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.Semantic proximity Read ↗

Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor.Semantic proximity Read ↗

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.Semantic proximity Read ↗

Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.Semantic proximity Read ↗

A New Monoclonal Antibody that Blocks KIT Dimerisation and Inhibits Gastrointestinal Stromal Tumour GrowthSemantic proximity Read ↗

A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor ModelsSemantic proximity Read ↗

The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.Semantic proximity Read ↗

Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.